FindMyKOL

Li Zhang, MD

Enriched profile

Hematology / Oncology

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Tacoma, WA · West · United StatesSpecialtyHematology / OncologyFocusLung Cancer (NSCLC/SCLC)+21
Active KOLFindMyKOL type: NationalLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Li Zhang is a Lung Cancer (NSCLC/SCLC) physician. ClinicalTrials.gov lists 182 registered studies with this person as an investigator.

Data verified 13 Nov 2026

Overview

Updated 13 Nov 2026

Li Zhang, M.D., is profiled from the public federal record. It also documents an investigator role on 182 registered clinical trials, industry payments reported by 29 companies.

  • Top research focus: Lung Cancer (NSCLC/SCLC)
  • 182 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 29 companies

Generated from the cited public record · current as of 13 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)92 trialsSmall Cell Lung Carcinoma65 trialsNasopharyngeal Carcinoma8 trialsNasopharyngeal Neoplasms7 trialsPharyngeal Neoplasms7 trialsStroke7 trialsCOVID-193 trialsNeoplasm Metastasis3 trialsOvarian / Gynecologic Cancer3 trialsBreast Cancer2 trialsColorectal Cancer2 trialsEsophageal Neoplasms2 trialsGlomerular Disease2 trialsInfertility2 trialsKidney Diseases2 trialsMelanoma2 trialsPain2 trialsProstate Cancer2 trialsAdenocarcinoma of Lung1 trialAnemia, Aplastic1 trialAzoospermia1 trialBladder / Urothelial Cancer1 trialBrain Injuries, Traumatic1 trialBrain Neoplasms1 trialCachexia1 trialCarcinoma, Squamous Cell1 trialCerebral Palsy1 trialColonic Neoplasms1 trialCoronary Artery Disease / ACS1 trialDepression (MDD)1 trialDiarrhea1 trialEmbolism1 trialFallopian Tube Neoplasms1 trialGastroesophageal Cancer1 trialHead & Neck Cancer1 trialHematologic Diseases1 trialHepatitis B1 trialHepatitis B, Chronic1 trialHypertrophy1 trialHypertrophy, Left Ventricular1 trialInfarction1 trialInflammation1 trialInfluenza, Human1 trialLupus (SLE)1 trialMesothelioma1 trialMesothelioma, Malignant1 trialMuscle Spasticity1 trialMyocardial Infarction1 trialNephritis1 trialNephrotic Syndrome1 trialNose Neoplasms1 trialOsteoarthritis1 trialParalysis1 trialPneumonia1 trialRectal Neoplasms1 trialKidney Cancer / RCC1 trialST Elevation Myocardial Infarction1 trialThromboembolism1 trialTics1 trialUterine Cervical Neoplasms1 trialVenous Thromboembolism1 trialViral Hepatitis (B/C)1 trialWounds and Injuries1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer (NSCLC/SCLC)Small Cell Lung CarcinomaNasopharyngeal CarcinomaNasopharyngeal NeoplasmsPharyngeal NeoplasmsBreast CancerEsophageal NeoplasmsMelanomaNeoplasm MetastasisOvarian / Gynecologic CancerBladder / Urothelial CancerBrain NeoplasmsCarcinoma, Squamous CellColorectal CancerGastroesophageal CancerHead & Neck CancerMesotheliomaMesothelioma, MalignantNose NeoplasmsProstate CancerRectal NeoplasmsUterine Cervical Neoplasms

Drugs & molecules

across trials, industry payments and publications
Imbruvicageneric · IbrutinibClinical trials—Industry payments13Publications—Enhertugeneric · TrastuzumabClinical trials—Industry payments9Publications—Epkinlygeneric · EpcoritamabClinical trials—Industry payments9Publications—Adcetrisgeneric · Brentuximab vedotinClinical trials—Industry payments7Publications—Elrexfiogeneric · ElranatamabClinical trials—Industry payments7Publications—Datrowaygeneric · Datopotamab deruxtecanClinical trials—Industry payments6Publications—Inqovigeneric · Cedazuridine / decitabineClinical trials—Industry payments5Publications—Lonsurfgeneric · Tipiracil / trifluridineClinical trials—Industry payments5Publications—Erleadageneric · ApalutamideClinical trials—Industry payments3Publications—Onivydegeneric · IrinotecanClinical trials—Industry payments3Publications—Darzalexgeneric · DaratumumabClinical trials—Industry payments2Publications—Jemperligeneric · DostarlimabClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Sun Yat-sen UniversityClinical trials44Industry payments—Abbvie Inc.Clinical trials—Industry payments14Sichuan Baili Pharmaceutical Co., Ltd.Clinical trials12Industry payments—AstraZeneca Pharmaceuticals LPClinical trials—Industry payments11Daiichi Sankyo Inc.Clinical trials—Industry payments9Jiangsu HengRui Medicine Co., Ltd.Clinical trials8Industry payments—Pfizer Inc.Clinical trials—Industry payments8University of Maryland, BaltimoreClinical trials8Industry payments—Janssen Biotech, Inc.Clinical trials—Industry payments6Betta Pharmaceuticals Co., Ltd.Clinical trials5Industry payments—Shanghai JMT-Bio Inc.Clinical trials5Industry payments—Taiho Oncology, Inc.Clinical trials—Industry payments5AkesoClinical trials4Industry payments—Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical trials4Industry payments—GlaxoSmithKline, LLC.Clinical trials—Industry payments4Ipsen Biopharmaceuticals, IncClinical trials—Industry payments4Qilu Pharmaceutical Co., Ltd.Clinical trials4Industry payments—Xie MingxingClinical trials4Industry payments—Bio-Thera SolutionsClinical trials3Industry payments—E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments3Jiangsu Alphamab Biopharmaceuticals Co., LtdClinical trials3Industry payments—Nanjing Leads Biolabs Co.,LtdClinical trials3Industry payments—Shenzhen TargetRx Co., Ltd.Clinical trials3Industry payments—Sunshine Lake Pharma Co., Ltd.Clinical trials3Industry payments—Ascentage Pharma Group Inc.Clinical trials2Industry payments—Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments2Eisai Inc.Clinical trials—Industry payments2EMD Serono, Inc.Clinical trials—Industry payments2Genfleet Therapeutics (Shanghai) Inc.Clinical trials2Industry payments—Innovent Biologics (Suzhou) Co. Ltd.Clinical trials2Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
182clinical trials

Investigator role on registered studies.

View trials ↓
29companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Nov 2026

Listed as an investigator on 182 registered studies on ClinicalTrials.gov. The most recent:

All 182 trial records: search, sort and filter.Explore →

Industry payments

Updated 13 Nov 2026

29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 40 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    75.5%
    Other antiemetics67.7%
    Fosaprepitant100%
    Part B, office-administered≥25 patients
    Serotonin-3 Receptor Antagonist5.3%
    Palonosetron hcl94%Ondansetron Odt6%
    Part D + Part B≥27 patients

    + 6 more classes in this area

  • Cancer & immunology

    8.4%
    Nucleoside Metabolic Inhibitor2.3%
    Fluorouracil100%
    Part B, office-administered≥12 patients
    Cytochrome P450 17A1 Inhibitor1.4%
    Abiraterone Acetate100%
    Part D≥18 patients

    + 8 more classes in this area

  • Sensory organs

    5.4%
    Corticosteroid5.4%
    Dexamethasone sodium phosphate93%Dexamethasone8%
    Part D + Part B≥38 patients
All 11 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0.3% facility · 99.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 13 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/iaslc_lungcancer-nsclc-oncology-activity-7368312205710123008-bTxk

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • Other

    onclive.com/view/dr-zhang-on-sacituzumab-tirumotecan-in-pretreated-advanced-egfr-mutated-nsclc

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.